158 related articles for article (PubMed ID: 10325583)
21. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis.
Lowe N; Feldman SR; Sherer D; Weiss J; Shavin JS; Lin YL; Foley V; Soto P
J Dermatolog Treat; 2005 Aug; 16(3):158-64. PubMed ID: 16096182
[TBL] [Abstract][Full Text] [Related]
22. Application of dermal microdialysis for the determination of bioavailability of clobetasol propionate applied to the skin of human subjects.
Au WL; Skinner MF; Benfeldt E; Verbeeck RK; Kanfer I
Skin Pharmacol Physiol; 2012; 25(1):17-24. PubMed ID: 21860254
[TBL] [Abstract][Full Text] [Related]
23. Chromatographic method for clobetasol propionate determination in hair follicles and in different skin layers.
Ângelo T; Cunha-Filho MS; Gelfuso GM; Gratieri T
Biomed Chromatogr; 2017 Feb; 31(2):. PubMed ID: 27502902
[TBL] [Abstract][Full Text] [Related]
24. Topical delivery of clobetasol propionate loaded microemulsion based gel for effective treatment of vitiligo--part II: rheological characterization and in vivo assessment through dermatopharmacokinetic and pilot clinical studies.
Patel HK; Barot BS; Parejiya PB; Shelat PK; Shukla A
Colloids Surf B Biointerfaces; 2014 Jul; 119():145-53. PubMed ID: 24767976
[TBL] [Abstract][Full Text] [Related]
25. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream.
Breneman D; Fleischer AB; Kaplan D; Lebwohl M; Miller B; Pariser D; Rist T; Swinyer L; Liu Y; Foley V
J Drugs Dermatol; 2005; 4(3):330-6. PubMed ID: 15898289
[TBL] [Abstract][Full Text] [Related]
26. The role of clobetasol propionate emollient 0.05% in the treatment of patients with dry, scaly, corticosteroid-responsive dermatoses.
Gordon ML
Clin Ther; 1998; 20(1):26-39. PubMed ID: 9522102
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of in vivo bioequivalence methodology for topical clobetasol 17-propionate based on pharmacodynamic modeling using Chinese skin.
Tsai JC; Cheng CL; Tsai YF; Sheu HM; Chou CH
J Pharm Sci; 2004 Jan; 93(1):207-17. PubMed ID: 14648650
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of anthralin inflammation. 2. Effect of pretreatment with glucocorticoids, anthralin and removal of stratum corneum.
Lawrence CM; Shuster S
Br J Dermatol; 1985 Jul; 113(1):117-22. PubMed ID: 4015968
[TBL] [Abstract][Full Text] [Related]
29. Different approaches for improving skin accumulation of topical corticosteroids.
Senyiğit T; Padula C; Ozer O; Santi P
Int J Pharm; 2009 Oct; 380(1-2):155-60. PubMed ID: 19635541
[TBL] [Abstract][Full Text] [Related]
30. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin.
Kolbe L; Kligman AM; Schreiner V; Stoudemayer T
Skin Res Technol; 2001 May; 7(2):73-7. PubMed ID: 11393207
[TBL] [Abstract][Full Text] [Related]
31. Effect of low frequency ultrasound on the in vitro percutaneous absorption of clobetasol 17-propionate.
Fang J; Fang C; Sung KC; Chen H
Int J Pharm; 1999 Nov; 191(1):33-42. PubMed ID: 10556738
[TBL] [Abstract][Full Text] [Related]
32. Relative efficacy and interchangeability ofvarious clobetasol propionate vehicles in the management of steroid-responsive dermatoses.
Feldman SR
Curr Ther Res Clin Exp; 2005 May; 66(3):154-71. PubMed ID: 24672120
[TBL] [Abstract][Full Text] [Related]
33. Topical application of clobetasol 17-propionate from various cream bases by using Wistar rat as an animal model.
Fang JY; Shen KL; Huang YB; Wu PC; Tsai YH
Kaohsiung J Med Sci; 1998 May; 14(5):286-93. PubMed ID: 9619014
[TBL] [Abstract][Full Text] [Related]
34. In Vivo Assessment of Clobetasol Propionate-Loaded Lecithin-Chitosan Nanoparticles for Skin Delivery.
Şenyiğit T; Sonvico F; Rossi A; Tekmen I; Santi P; Colombo P; Nicoli S; Özer Ö
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28035957
[TBL] [Abstract][Full Text] [Related]
35. Distribution of salicylic acid in human stratum corneum following topical application in vivo: a comparison of six different formulations.
Tsai J; Chuang S; Hsu M; Sheu H
Int J Pharm; 1999 Oct; 188(2):145-53. PubMed ID: 10518670
[TBL] [Abstract][Full Text] [Related]
36. Clobetasol-loaded nanostructured lipid carriers for epidermal targeting.
Silva LA; Andrade LM; de Sá FA; Marreto RN; Lima EM; Gratieri T; Taveira SF
J Pharm Pharmacol; 2016 Jun; 68(6):742-50. PubMed ID: 27061573
[TBL] [Abstract][Full Text] [Related]
37. A novel foam vehicle for delivery of topical corticosteroids.
Huang X; Tanojo H; Lenn J; Deng CH; Krochmal L
J Am Acad Dermatol; 2005 Jul; 53(1 Suppl 1):S26-38. PubMed ID: 15968261
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamics and dermatopharmacokinetics of betamethasone 17-valerate: assessment of topical bioavailability.
Wiedersberg S; Naik A; Leopold CS; Guy RH
Br J Dermatol; 2009 Mar; 160(3):676-86. PubMed ID: 18782322
[TBL] [Abstract][Full Text] [Related]
39. Correlation between the drug penetration and the blanching effect of topically applied hydrocortisone creams in human beings.
Caron D; Queille-Roussel C; Shah VP; Schaefer H
J Am Acad Dermatol; 1990 Sep; 23(3 Pt 1):458-62. PubMed ID: 2212144
[TBL] [Abstract][Full Text] [Related]
40. Penetration studies of topically applied substances: Optical determination of the amount of stratum corneum removed by tape stripping.
Lademann J; Ilgevicius A; Zurbau O; Liess HD; Schanzer S; Weigmann HJ; Antoniou C; Pelchrzim RV; Sterry W
J Biomed Opt; 2006; 11(5):054026. PubMed ID: 17092175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
